Site Search
Professionals 400 results
Capabilities 76 results
Practice Area
Product Liability & Mass Torts
Major multinational companies trust Winston to defend their products and reputations in high-profile, high-stakes product liability and mass tort claims. Our Product Liability & Mass Torts Practice is one of the industry’s most seasoned, with a deep bench of experienced lawyers and a unique combination of extensive trial experience and expansive technical knowledge.
Practice Area
Derivatives & Structured Products
Winston represents swap dealers, major swap participants, financial intermediaries, hedge funds, national exchanges, and end-users in a broad array of derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement issues related to commodities and derivatives.
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Experience 129 results
Experience
|June 4, 2025
Winston Represents Chart Industries in All-Stock Merger of Equals with Flowserve
Experience
|May 27, 2025
Experience
|April 11, 2025
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
Insights & News 2,098 results
Competition Corner
|June 18, 2025
|2 Min Read
Enforcers Provide Guidance and Warnings for In-House Antitrust Lawyers at CLA Summit
The California Lawyers Association’s Antitrust and Unfair Competition Law hosted its inaugural In-House Counsel Summit on May 15, 2025, at the Computer History Museum in Menlo Park, California.
Client Alert
|June 12, 2025
|3 Min Read
Oregon Enacts SB 951, Restricting PE-Backed MSOs in Physician Practice Transactions
On June 9, 2025, Oregon enacted Senate Bill 951 (SB 951), a sweeping new law significantly limiting how management services organizations (MSOs)—including those backed by private-equity firms—may engage with physician practices. The legislation targets traditional “friendly provider” models by restricting ownership and operational control of professional medical entities and voiding restrictive covenants. Investors must now reassess Oregon-based physician practice investments to ensure compliance by 2026 (for new MSOs) and 2029 (for existing ones). It’s noteworthy that this law will coexist with Oregon’s complicated health care transactions notice law, a law that requires a thorough review of certain health care transactions.
Recognitions
|June 12, 2025
|1 Min Read
Winston & Strawn Recognized in The Legal 500 U.S. 2025
Winston & Strawn is recognized as a top-tier firm in five areas and recommended in an additional 45 categories in the 2025 edition of The Legal 500 U.S. In addition, eight lawyers are listed in the Hall of Fame, four lawyers are recognized as Leading Trial Lawyers, 16 partners were ranked as Leading Partners, four associates are ranked as Leading Associates, one partner is ranked as a Leading Lawyer, five lawyers are recognized as Next Generation Partners, and two lawyers are listed as Rising Stars. A total of 186 lawyers are mentioned by name in Legal 500 United States commentary for their standout contribution to respective practices.
Other Results 85 results
Law Glossary
What Are Interchangeable Biological Products?
A biological product is interchangeable if it is biosimilar to the reference product and is expected to produce the same clinical result as the reference product in any given patient. A biosimilar product that is deemed to be interchangeable by the FDA means the biosimilar product can be substituted for the reference product by a pharmacist without consulting the prescriber. The specific requirements for substitution vary by state.
Site Content
In the product liability context, general causation is the legal and scientific determination of whether the product in question has the inherent capability to cause the alleged injury under certain circumstances. Establishment of general causation is a critical aspect of a plaintiff’s case, and typically requires scientific evidence, such as epidemiology or toxicology, and expert testimony to establish a causal connection between the product’s design, manufacturing, or warnings and the injury or injuries at issue. As contrasted to specific causation, the focus in a general causation inquiry is on whether the product or exposure, as a general matter, can cause the type of injury claimed by the plaintiff. A general causation inquiry does not assess any facts unique to a particular plaintiff.
Site Content
A subset of biologics, a biosimilar is a biologic that is highly similar to an FDA-approved product, referred to as the reference product. Biosimilars have no clinically meaningful differences compared to a reference product in terms of safety, purity, and potency as demonstrated through human pharmacokinetic and pharmacodynamics studies. Because of their complexity, biosimilars are unlikely to be identical replicates of their comparable reference products.